Anti-Human CD307e (FcRL5) In Vivo Antibody - Low Endotoxin
Introducing the Anti-Human CD307e [FcRL5] In Vivo Antibody - Low Endotoxin from Assay Genie, a highly specific monoclonal antibody designed for in vivo applications.
This antibody targets the CD307e (Fc receptor-like 5) protein, a surface molecule implicated in the regulation of B-cell function. This makes it an exceptional choice for research in immunology and related disciplines. With a mouse IgG1 isotype, it ensures high purity and low endotoxin levels (<1.0 EU/mg), perfect for ELISA, flow cytometry, immunohistochemistry, and other assays. Available in various sizes, it is formulated in phosphate-buffered saline for maximum stability and efficacy. Enhance your research with this reliable and versatile antibody. CD307e (FcRL5) is expressed on the surface of B-cells and certain other immune cells, playing a role in modulating immune responses. Understanding and manipulating this protein can provide valuable insights into immune regulation and potential therapeutic targets for immune-related diseases.
Product Name:
Anti-Human CD307e (FcRL5) In Vivo Antibody - Low Endotoxin
Product Code:
IVMB0369
Size:
1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:
509F6
Protein:
FcRL5
Product Type:
Monoclonal Antibody
Synonyms:
CD307e, CD307, BXMAS1, FCRH5, Fc receptor-like protein 5, IRTA2
Isotype:
IgG2a k
Reactivity:
Human
Applications:
B, FC, In Vivo, IP
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Product Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Applications:
B, FC, In Vivo, IP
Reactivity:
Human
Host Species:
Mouse
Specificity:
Clone 50946 recognizes human FcRL5 within the first 3 Ig domains. Clone 50946 does not cross-react with FcRL4.
Antigen Distribution:
FcRL5 is expressed on mature B cells and plasma cells.
Immunogen:
Cells transfected with Human FcRL5.
Concentration:
≥ 5.0 mg/ml
Endotoxin Level:
< 1.0 EU/mg as determined by the LAL method
Formulation:
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:
≥95% monomer by analytical SEC â‹… >95% by SDS Page
Preparation:
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
FcRL5 antibody, 509F6, recognizes Fc receptor-like 5 (FcRL5), also known as immunoglobulin superfamily receptor translocation associated 2 (IRTA2), Fc receptor homolog 5 (FcRH5), and BXMAS1. FcRL5 is a 106 kDa type I transmembrane glycoprotein containing 9 Ig-like extracellular domains, a cytoplasmic ITAM-like consensus sequence, and two cytoplasmic ITIM-like sequences1. FcRL5 is found on most mature B cells, with the highest levels on naive and memory B cells and plasma cells1,2. FcRL5 is an IgG receptor and binds to all IgG isotypes3, resulting in the inhibition of BCR signaling through the recruitment of SH2 domain-containing tyrosine phosphatase 1 (SHP-1) after tyrosine phosphorylation of its two ITIMs4. B cell malignancies, including multiple myeloma, chronic lymphocytic leukemia, mantle cell lymphoma, and hairy cell leukemia, often exhibit aberrant FCRL5 expression, indicating FcRL5 as a potential biomarker or therapeutic target5-7.
